Form SC 13G/A Forma Therapeutics Holdi Filed by: Cormorant Asset Management, LP
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Oppenheimer Starts Forma Therapeutics (FMTX) at Outperform
February 17, 2021 6:58 AM ESTOppenheimer analyst Mark Breidenbach initiates coverage on Forma Therapeutics (NASDAQ: FMTX) with a Outperform rating and a price target of $60.00.
The analyst comments "We initiate coverage of Forma Therapeutics, which has assembled an impressive pipeline of targeted therapies for rare diseases... More
